Biopharmaceutical News and Research

RSS

Paratek initiates Omadacycline phase 3 clinical study in community acquired bacterial pneumonia (CABP)

Paratek Pharmaceuticals, Inc. has announced the dosing of the first patient in its Phase 3 clinical study of its lead drug candidate, omadacycline, for the treatment of Community Acquired Bacterial Pneumonia (CABP). This global Phase 3 study will assess the efficacy and safety of omadacycline compared with moxifloxacin in subjects with CABP.

9 Nov 2015

AACR rapid and dramatic responses in TRK fusion patients

Loxo Oncology, Inc., a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced new results from its Phase 1 open-label, dose-escalation trial of LOXO-101, a selective inhibitor of tropomyosin receptor kinase (TRK) signaling molecules, and the first preclinical data for its RET and FGFR programs. The data are being presented at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

9 Nov 2015

Nightstar announces $35 million Series B financing round

NightstaRx Ltd, a biopharmaceutical company specialising in developing gene therapies for inherited retinal dystrophies, announces a $35 million Series B financing round. The round was led by New Enterprise Associates, one of the world's leading venture capital firms.

9 Nov 2015

Circulating protein predicts risk of chronic kidney disease

Make room, cholesterol. A new disease marker is entering the medical lexicon: suPAR, or soluble urokinase-type plasminogen activator receptor.

6 Nov 2015

MD Anderson Cancer Center, CytomX to study probody-enabled CAR-NK cell therapies

CytomX Therapeutics, a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, today entered into a collaboration with The University of Texas MD Anderson Cancer Center to research Probody-enabled chimeric antigen receptor natural killer (CAR-NK) cell therapies, to be known as ProCAR-NK cell therapies.

6 Nov 2015

Johnson & Johnson signs definitive agreement to purchase Novira Therapeutics

Johnson & Johnson today announced a definitive agreement to acquire Novira Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company developing novel therapies for curative treatment of chronic hepatitis B virus (HBV) infection.

4 Nov 2015

Alnylam presents positive ongoing phase 2 open-label extension data for Patisiran and Revusiran

Alnylam Pharmaceuticals, Inc. has announced new results from its ongoing Phase 2 open-label extension (OLE) studies with patisiran and revusiran, investigational RNAi therapeutics targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR amyloidosis).

3 Nov 2015

$Viking begins VK5211 Phase 2 trial in patients recovering from hip fracture$

Viking begins VK5211 Phase 2 trial in patients recovering from hip fracture

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced the initiation of dosing in the company's Phase 2 clinical trial of VK5211 in patients who recently suffered a hip fracture.

3 Nov 2015

CureVac raises €100M to enable rapid expansion of mRNA development platform, clinical-stage pipeline

CureVac, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based technology, today announces that it has raised about $110 million (€100 million) to enable accelerated expansion of its industry-leading messenger RNA (mRNA) development platform and clinical-stage pipeline.

3 Nov 2015

Mallinckrodt announces approval of INOmax for cardiovascular surgery in Australia and Japan

Mallinckrodt plc, a leading specialty biopharmaceutical company, today announced that INOmax (nitric oxide) for inhalation has received regulatory approval in Australia and Japan for pulmonary hypertension in conjunction with heart surgery.

30 Oct 2015

Ultragenyx, Arcturus sign agreement to develop mRNA therapeutics to certain rare diseases

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, and Arcturus Therapeutics, Inc., a leading RNA medicines company, today announced that they have entered into a research collaboration and license agreement to discover and develop messenger RNA (mRNA) therapeutics to certain rare disease targets using Arcturus' UNA Oligomer chemistry and LUNAR nanoparticle delivery platform.

29 Oct 2015

IMBRUVICA (ibrutinib) wins Prix Galien USA 2015 Award in Best Pharmaceutical Agent category

Today, IMBRUVICA (ibrutinib) was awarded the prestigious Prix Galien USA 2015 Award in the category of Best Pharmaceutical Agent. The Prix Galien Award is considered to be the industry's highest accolade and recognizes the vital technical, scientific and clinical research skills necessary to develop medicines.

28 Oct 2015

Mast Therapeutics begins vepoloxamer Phase 2 study in patients with chronic heart failure

Mast Therapeutics, Inc., a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for sickle cell disease, heart failure, and stroke, announced that it has initiated its Phase 2 study of vepoloxamer for the treatment of patients with chronic heart failure.

26 Oct 2015

Sinovac Dalian receives approval to start human clinical trials of varicella vaccine candidate

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, today announced that one of its subsidiaries, Sinovac Dalian, has received approval to begin human clinical trials on its varicella vaccine candidate. The clinical trial application for the varicella vaccine was officially accepted by the China Food and Drug Administration in January 2013.

26 Oct 2015

Medlab granted ethics approval to begin human trials using nanotechnology delivery platform

Sydney-based, ASX listed, biopharmaceutical company, Medlab Clinical Ltd has been granted ethics approval to progress to two separate human trials using its nanotechnology delivery platform.

23 Oct 2015

Viking successfully completes safety, tolerability and pharmacokinetic study of VK5211 in elderly subjects

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced the successful completion of a short-term safety, tolerability, and pharmacokinetic study of VK5211 in healthy elderly subjects. VK5211, the company's lead program for muscle and bone disorders, is an orally available, non-steroidal selective androgen receptor modulator (SARM) being developed for the treatment of patients recovering from non-elective hip fracture surgery.

20 Oct 2015

Ember Therapeutics reports initial results from BMP-7 Phase II trial in patients with moderate osteoarthritis of the knee

Ember Therapeutics, Inc., a privately held, New York-based biopharmaceutical company that is developing targeted therapies for osteoarthritis, kidney fibrosis, and other indications using Bone Morphogenetic Protein (BMP)-7, announced today initial results from the Phase II(a) trial of local BMP-7 administration in patients with moderate osteoarthritis of the knee.

20 Oct 2015

DelMar reports positive data from preclinical study of VAL-083 for treatment of ovarian cancer

DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced that yesterday it presented positive preclinical data demonstrating the promising potential of its lead product candidate VAL-083 (dianhydrogalactitol) as a treatment for ovarian cancer.

19 Oct 2015

Aratana announces $40 million senior secured credit facility

Aratana Therapeutics, Inc., a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, today announced a $40 million senior secured credit facility with Pacific Western Bank, as agent and lender, and Oxford Finance LLC, as lender. The facility refinances the $15 million loan facility previously provided to the Company by Pacific Western Bank (as successor-in-interest to Square 1 Bank).

16 Oct 2015

Merck unveils new global brand as a science and technology company

Merck, a leading science and technology company, today announced the relaunch of its brand identity. The fundamental revision of the visual appearance as well as the introduction of a new logo reflect the transformation into a global science and technology company. At the same time, the brand architecture at business level has been simplified. Outside the United States and Canada, the company will operate uniformly as Merck.

15 Oct 2015

Biopharmaceutical News and Research

Paratek initiates Omadacycline phase 3 clinical study in community acquired bacterial pneumonia (CABP)

AACR rapid and dramatic responses in TRK fusion patients

Nightstar announces $35 million Series B financing round

Circulating protein predicts risk of chronic kidney disease

MD Anderson Cancer Center, CytomX to study probody-enabled CAR-NK cell therapies

Johnson & Johnson signs definitive agreement to purchase Novira Therapeutics

Alnylam presents positive ongoing phase 2 open-label extension data for Patisiran and Revusiran

Viking begins VK5211 Phase 2 trial in patients recovering from hip fracture

CureVac raises €100M to enable rapid expansion of mRNA development platform, clinical-stage pipeline

Mallinckrodt announces approval of INOmax for cardiovascular surgery in Australia and Japan

Ultragenyx, Arcturus sign agreement to develop mRNA therapeutics to certain rare diseases

IMBRUVICA (ibrutinib) wins Prix Galien USA 2015 Award in Best Pharmaceutical Agent category

Mast Therapeutics begins vepoloxamer Phase 2 study in patients with chronic heart failure

Sinovac Dalian receives approval to start human clinical trials of varicella vaccine candidate

Medlab granted ethics approval to begin human trials using nanotechnology delivery platform

Viking successfully completes safety, tolerability and pharmacokinetic study of VK5211 in elderly subjects

Ember Therapeutics reports initial results from BMP-7 Phase II trial in patients with moderate osteoarthritis of the knee

DelMar reports positive data from preclinical study of VAL-083 for treatment of ovarian cancer

Aratana announces $40 million senior secured credit facility

Merck unveils new global brand as a science and technology company

Pittcon Highlights: Pharmaceutical & Biologic eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News